Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 6 · 75%Low 2 · 25%Moderate 0 · 0%High 0 · 0%

TACE followed by 3‐DCRT vs chemoembolisation

All‐cause mortality: at 3 years · primary hepatocellular carcinoma

TACE followed by 3‐DCRT may leads to lower all‐cause mortality: at 3 years compared with TACE (low certainty).

1 finding from 1 review

Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
RR 0.8 [0.73, 0.88]
7 studies · 552 participants
Low

TACE followed by 3‐DCRT vs chemoembolisation

Proportion of participants without tumour response (CR+PR) · primary hepatocellular carcinoma

TACE followed by 3‐DCRT may leads to lower proportion of participants without tumour response (CR+PR) compared with TACE (low certainty).

1 finding from 1 review

Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
RR 0.49 [0.39, 0.61]
8 studies · 632 participants
Low

TACE followed by 3‐DCRT vs chemoembolisation

Serious adverse events · primary hepatocellular carcinoma

1 finding from 1 review

Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

TACE followed by 3‐DCRT vs chemoembolisation

Health‐related quality of life · primary hepatocellular carcinoma

1 finding from 1 review

Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 66 participants
Very low

TACE followed by 3‐DCRT vs chemoembolisation

Non‐serious adverse events: leukopenia · primary hepatocellular carcinoma

It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: leukopenia compared with TACE (very low certainty).

1 finding from 1 review

Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
RR 1.12 [0.92, 1.34]
5 studies · 438 participants
Very low

TACE followed by 3‐DCRT vs chemoembolisation

Non‐serious adverse events: serum transaminases elevation · primary hepatocellular carcinoma

It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: serum transaminases elevation compared with TACE (very low certainty).

1 finding from 1 review

Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
RR 1.67 [0.66, 4.27]
4 studies · 280 participants
Very low

TACE followed by 3‐DCRT vs chemoembolisation

Non‐serious adverse events: total bilirubin elevation · primary hepatocellular carcinoma

It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: total bilirubin elevation compared with TACE (very low certainty).

1 finding from 1 review

Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
RR 2.69 [1.34, 5.4]
2 studies · 172 participants
Very low

TACE followed by 3‐DCRT vs chemoembolisation

Proportion of participants without serum AFP normalisation · primary hepatocellular carcinoma

It is very uncertain whether TACE followed by 3‐DCRT changes proportion of participants without serum AFP normalisation compared with TACE (very low certainty).

1 finding from 1 review

Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 96 participants
Very low